Patience during this adjustment period supports long-term success and medication adherence
Common Mistakes We See (And How to Avoid Them) Over the years, our team has troubleshooted countless research issues, and we've seen some recurring themes
Three key findings result from our study: (1) pwIIH treated with GLP-1-RAs lose significantly more weight than pwIIH electing for UCWM only, (2) treatment with GLP-1-RAs is associated with favorable headache outcomes, and (3) treatment with GLP-1-RAs is not associated with any severe adverse events in IIH, and thus presents a safe treatment option for weight management in pwIIH
The internet wants this to be a definitive step change
We know about these interactions because Novo Nordisk, the manufacturer of FDA-approved Wegovy, Ozempic, and Rybelsus, is required to report adverse events to the FDA
Real-world persistence data will be particularly important to guide efforts for shoring up the chronic market opportunity, e.g., via digital health support programmes, such as the Omada Health-Evernorth partnership [8]